Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/can-intravesical-bacillus-calmette-gu-rin-reduce-recurrence-in-C0Xip1HESV
References (41)
-
T. Kemp, Aaron Ludwig, J. Earel, Jill Moore, R. Vanoosten, B. Moses, K. Leidal, W. Nauseef, T. Griffith (2005)
Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.Blood, 106 10
-
S. Hinotsu, H. Akaza, S. Isaka, H. Kanetake, Y. Kubota, M. Kuroda, N. Shinohara, T. Shinka, M. Tachibana, S. Naito, Y. Hirao (2006)
Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.Urology, 67 3
-
K. Yoo, Tae Lim, Sung‐Goo Chang (2012)
Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute.Experimental and therapeutic medicine, 3 2
-
M. Hall, Sam Chang, G. Dalbagni, R. Pruthi, J. Seigne, E. Skinner, J. Wolf, P. Schellhammer (2007)
Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.The Journal of urology, 178 6
-
A. Böhle (2002)
Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.International braz j urol : official journal of the Brazilian Society of Urology, 28 6
-
R. Järvinen, E. Kaasinen, A. Sankila, E. Rintala (2009)
Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.European urology, 56 2
-
M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou-Redorta (2008)
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder.European urology, 54 2
-
M. Friedrich, U. Pichlmeier, H. Schwaibold, S. Conrad, H. Huland (2007)
Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.European urology, 52 4
-
V. Startsev, I. Pouline (2005)
Adjuvant therapy in different risk-groups of patients with superficial bladder cancer.Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 77 2
-
H. Koga, S. Ozono, T. Tsushima, K. Tomita, Y. Horiguchi, M. Usami, Y. Hirao, H. Akaza, S. Naito (2010)
Maintenance intravesical bacillus Calmette‐Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: Randomized controlled trial by the BCG Tokyo Strain Study GroupInternational Journal of Urology, 17
-
G. Lorenzo, S. Perdoná, R. Damiano, A. Faiella, F. Cantiello, S. Pignata, P. Ascierto, E. Simeone, M. Sio, R. Autorino (2010)
Gemcitabine versus bacille Calmette‐Guérin after initial bacille Calmette‐Guérin failure in non‐muscle‐invasive bladder cancerCancer, 116
-
J. Kulkarni, R. Gupta (2002)
Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette‐Guérin (Danish 1331 strain)BJU International, 90
-
F. Kunieda, H. Kitamura, M. Niwakawa, Kentaro Kuroiwa, N. Shinohara, K. Tobisu, Kenichi Nakamura, T. Shibata, T. Tsuzuki, T. Tsukamoto, Y. Kakehi (2012)
Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology after second transurethral resection: Japan Clinical Oncology Group Study JCOG1019.Japanese journal of clinical oncology, 42 11
-
T. Okamura, H. Akita, R. Ando, Y. Ikegami, T. Naiki, N. Kawai, K. Tozawa, K. Kohri (2012)
Single monthly bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancerInternational Journal of Clinical Oncology, 17
-
M. Brausi, J. Witjes, D. Lamm, R. Persad, J. Palou, M. Colombel, R. Buckley, M. Soloway, H. Akaza, A. Böhle (2011)
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.The Journal of urology, 186 6
-
S. Hinotsu, H. Akaza, S. Naito, S. Ozono, Y. Sumiyoshi, Sumio Noguchi, A. Yamaguchi, S. Nagamori, A. Terai, Y. Nasu, H. Kume, Y. Tomita, Yoshinori Tanaka, S. Samma, H. Uemura, H. Koga, T. Tsushima (2011)
Maintenance therapy with bacillus Calmette‐Guérin Connaught strain clearly prolongs recurrence‐free survival following transurethral resection of bladder tumour for non‐muscle‐invasive bladder cancerBJU International, 108
-
S. Stasi, A. Giannantoni, A. Giurioli, M. Valenti, G. Zampa, L. Storti, F. Attisani, Andrea Carolis, G. Capelli, G. Vespasiani, R. Stephen (2006)
Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial.The Lancet. Oncology, 7 1
-
Chung-Hsin Chen, Hung-Ju Yang, C. Shun, Chao-yuan Huang, Kuo-How Huang, Hong‐Jeng Yu, Y. Pu (2012)
A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.Urologic oncology, 30 4
-
M. Porena, M. Zingaro, M. Lazzeri, L. Mearini, A. Giannantoni, V. Bini, E. Costantini (2010)
Bacillus Calmette-Guérin versus Gemcitabine for Intravesical Therapy in High-Risk Superficial Bladder Cancer: A Randomised Prospective StudyUrologia Internationalis, 84
-
Shan-hong Yi, G. Ye, Xiang-wei Wang, Huan-Sheng Jin, Yuan-ning Zhang, Zhi-Lin Yan (2008)
[Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].Ai zheng = Aizheng = Chinese journal of cancer, 27 11
-
P. Malmström, H. Wijkström, Carl Lundholm, K. Wester, C. Busch, B. Norlén (1999)
5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.The Journal of urology, 161 4
-
T. Cai, G. Nesi, G. Tinacci, E. Zini, N. Mondaini, V. Boddi, S. Mazzoli, R. Bartoletti (2008)
Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.The Journal of urology, 180 1
-
W. Oosterlinck, Z. Kirkali, R. Sylvester, F. Silva, C. Busch, F. Algaba, S. Collette, A. Bono (2011)
Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993).European urology, 59 3
-
R. Han, Jian-gang Pan (2006)
Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.Urology, 67 6
-
M. Duchek, R. Johansson, S. Jahnson, O. Mestad, P. Hellström, S. Hellsten, P. Malmström (2010)
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.European urology, 57 1
-
S. Aldousari, W. Kassouf (2013)
Update on the management of non-muscle invasive bladder cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 4 1
-
C. Cheng, Siu Chan, L. Chan, C. Chan, C. Ng, H. Cheung, S. Chan, W. Wong, F. Lai, K. To, M. Li (2005)
Twelve‐year follow up of a randomized prospective trial comparing bacillus Calmette‐Guerin and epirubicin as adjuvant therapy in superficial bladder cancerInternational Journal of Urology, 12
-
M. Shelley, M. Mason, H. Kynaston (2010)
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses.Cancer treatment reviews, 36 3
-
D Eidinger A Morales (1976)
Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumorsJ Urol, 116
-
A. Ojea, J. Nogueira, E. Solsona, N. Flores, J. Gómez, J. Molina, V. Chantada, J. Camacho, L. Piñeiro, R. Rodríguez, S. Isorna, M. Blas, J. Martinez-Pineiro, R. Madero (2007)
A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.European urology, 52 5
-
D. Cho, Jh Bae, D. Moon, J. Cheon, J.G. Lee, J. Kim, DK Yoon, H. Park (2009)
The Effects of Intravesical Chemoimmunotherapy with Gemcitabine and Bacillus Calmette-Guérin in Superficial Bladder Cancer: A Preliminary StudyJournal of International Medical Research, 37
-
Ó. Faba, J. Palou, A. Breda, H. Villavicencio (2012)
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatmentWorld Journal of Urology, 30
-
I. Cho, Eun Kim, J. Joung, H. Seo, Jinsoo Chung, W. Park, K. Lee (2012)
Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea.Anticancer research, 32 4
-
C. Bilen, H. Özen, F. Aki, C. Aygün, S. Ekici, S. Kendi (2000)
Clinical experience with BCG alone versus BCG plus epirubicinInternational Journal of Urology, 7
-
D. Lamm, B. Blumenstein, J. Crissman, J. Montie, J. Gottesman, B. Lowe, M. Sarosdy, Robert Bohl, H. Grossman, T. Beck, J. Leimert, E. Crawford (2000)
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.The Journal of urology, 163 4
-
R. Sylvester, M. Brausi, W. Kirkels, W. Hoeltl, F. Silva, P. Powell, S. Prescott, Z. Kirkali, C. Beek, T. Gorlia, T. Reijke (2010)
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladdEuropean urology, 57 5
-
G. Kulkarni, O. Hakenberg, J. Gschwend, G. Thalmann, W. Kassouf, A. Kamat, A. Zlotta (2010)
An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.European urology, 57 1
-
K. Matsumoto, E. Kikuchi, H. Shirakawa, N. Hayakawa, N. Tanaka, Akiharu Ninomiya, A. Miyajima, So Nakamura, M. Oya (2012)
Risk of subsequent tumour recurrence and stage progression in bacille Calmette‐Guérin relapsing non‐muscle‐invasive bladder cancerBJU International, 110
-
L. Koskela, M. Poljakovic, I. Ehrén, N. Wiklund, P. Verdier (2012)
Localization and expression of inducible nitric oxide synthase in patients after BCG treatment for bladder cancer.Nitric oxide : biology and chemistry, 27 3
-
Ö. Gülpınar, Ahmet Halilioglu, M. Gökçe, Ç. Göğüş, S. Baltacı (2012)
The value of perioperative mitomycin C instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study.International braz j urol : official journal of the Brazilian Society of Urology, 38 4
-
M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou-Redorta, M. Rouprêt (2011)
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.European urology, 59 6
- Publisher
- Springer Journals
- Copyright
- 2014 Higher Education Press and Springer-Verlag Berlin Heidelberg
- ISSN
- 2095-0217
- eISSN
- 2095-0225
- DOI
- 10.1007/s11684-014-0328-0
- Publisher site
- See Article on Publisher Site
Abstract
Abstract Approximately 70% of newly diagnosed bladder tumors are non-muscle invasive bladder cancer (NMIBC). NMIBC accounts for approximately 80% of total bladder cancer cases. Bacillus Calmette-Guérin (BCG) instillation and maintenance is considered as the standard adjuvant treatment for superficial bladder cancer. A number of randomized studies have focused on the benefit of maintenance therapy following initial BCG induction. To provide further insights into the effect of intravesical instillation on recurrence in patients with NMIBC, we analyzed this relationship by conducting an updated detailed meta-analysis. Evidence suggested that adjuvant intravesical BCG with maintenance treatment is significantly effective for the prophylaxis of tumor recurrence in patients with NMIBC.
Journal
"Frontiers of Medicine" – Springer Journals
Published: Jun 1, 2014